IRVINE, Calif., Oct. 12, 2017 (GLOBE NEWSWIRE) — Central Admixture Pharmacy Services, Inc. (CAPS®), will showcase its sustained commitment to improving patient safety at the 2017 Health Connect Conference in Chicago, IL, Oct. 16-18.
At booth #508, CAPS representatives will introduce the company’s latest 90-Day Beyond Use Dating (BUD) quality assurance offering for pre-filled syringes and other products, which is designed to improve the waste reduction process. This initiative further complements CAPS’ current extended BUD offerings.
CAPS has been a front-runner in implementing the Food and Drug Administration’s (FDA) 503B quality assurance requirements under the Drug Quality and Security Act. During the conference, CAPS will highlight its Test, Hold and ReleaseSM (THR®) program, which is designed to ensure that every compounded drug batch from CAPS’ 503B outsourcing facilities meets the new standards for 100% cGMP release testing for sterility, potency, and endotoxin prior to release and shipment. CAPS also offers a Certificate of Release for each batch to give customers peace of mind.
“Our existing high quality standards are strengthened with THR implementation,” said Mike Koch, Senior Vice President, CAPS Professional Services. “When it comes to patient safety, we believe that …